Author:
Zec Simon,Tharian Antony,Candido Kenneth D.,Knezevic Nebojsa Nick
Publisher
Springer International Publishing
Reference102 articles.
1. Bhana N, Goa KL, McClellan KJ. Dexmedetomidine. Drugs. 2000;59(2):263–8. discussion 9–70.
2. Weerink MAS, Struys M, Hannivoort LN, Barends CRM, Absalom AR, Colin P. Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. Clin Pharmacokinet. 2017;56(8):893–913.
3. US Food and Drug Administration. Precedex label. 1999. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021038s017lbl.pdf .
4. Weatherall M, Aantaa R, Conti G, Garratt C, Pohjanjousi P, Lewis MA, et al. A multinational, drug utilization study to investigate the use of dexmedetomidine (Dexdor(R)) in clinical practice in the EU. Br J Clin Pharmacol. 2017;83(9):2066–76.
5. European Medicines Agency. Dexdor: EPAR – Product Information. 2018. Available from: https://www.ema.europa.eu/documents/product-information/dexdor-epar-product-information_en.pdf .